BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 22898539)

  • 1. The role of mutations in epigenetic regulators in myeloid malignancies.
    Shih AH; Abdel-Wahab O; Patel JP; Levine RL
    Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Epigenetic Modifications in Myeloid Malignancies.
    Venney D; Mohd-Sarip A; Mills KI
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research on molecular markers for epigenetic changes in myeloid malignancies].
    Li L; Sun XM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Dec; 30(6):687-92. PubMed ID: 24327148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
    Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
    J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in epigenetic regulators in myelodysplastic syndromes.
    Nikoloski G; van der Reijden BA; Jansen JH
    Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
    Chotirat S; Thongnoppakhun W; Wanachiwanawin W; Auewarakul CU
    Blood Cells Mol Dis; 2015 Mar; 54(3):286-91. PubMed ID: 25486927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
    Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY; Zhou Y; Xu MJ; Yang FC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC; Agosto-Peña J
    Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
    McDevitt MA
    Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid malignancies: mutations, models and management.
    Murati A; Brecqueville M; Devillier R; Mozziconacci MJ; Gelsi-Boyer V; Birnbaum D
    BMC Cancer; 2012 Jul; 12():304. PubMed ID: 22823977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
    Larsson CA; Cote G; Quintás-Cardama A
    Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].
    Wang JY; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1303-9. PubMed ID: 22040993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
    Fujino T
    Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
    Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
    Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
    Kurt H; Bueso-Ramos CE; Khoury JD; Routbort MJ; Kanagal-Shamanna R; Patel UV; Jorgensen JL; Wang SA; Ravandi F; DiNardo C; Luthra R; Medeiros LJ; Patel KP
    Am J Surg Pathol; 2018 May; 42(5):569-577. PubMed ID: 29635257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.